12-Month Stability of Diurnal IOP Control on Cosopt

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Anthony D. Realini, West Virginia University
ClinicalTrials.gov Identifier:
NCT00379834
First received: September 21, 2006
Last updated: June 27, 2012
Last verified: June 2012

September 21, 2006
June 27, 2012
September 2006
April 2008   (final data collection date for primary outcome measure)
Diurnal IOP control [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Diurnal IOP control
  • Adverse events
Complete list of historical versions of study NCT00379834 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
12-Month Stability of Diurnal IOP Control on Cosopt
12-Month Stability of Diurnal IOP Control on Cosopt

To determine the stability of diurnal intraocular pressure in eyes with glaucoma treated with Cosopt

Glaucoma is a potentially-blinding but treatable eye disease. A major risk factor for glaucoma is elevated intraocular pressure (IOP). IOP is a dynamic variable (like blood pressure)—it changes over time. The more it changes, the more likely patients are to get worse. Glaucoma is treated by lowering IOP. Cosopt is a medication that lowers IOP. Little is known about how well Cosopt reduces IOP fluctuations. In this study, we plan to measure the IOP in both eyes of 10 glaucoma patients treated with Cosopt, every 2 hours from 8am to 8pm, on five separate days over a one-year period. Untreated baseline IOP will be measured on a similar long day before beginning treatment with Cosopt. This methodology will allow us to compare IOP fluctuations with and without Cosopt, and also to learn about long-term control of IOP fluctuations in eyes treated with Cosopt.

Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Glaucoma
Drug: Cosopt
Cosopt BID OU
Active Comparator: Cosopt
Cosopt BID OU
Intervention: Drug: Cosopt
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
April 2008
April 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • bilateral OAG

Exclusion Criteria:

  • contraindications to Cosopt
  • pathology affecting tonometry
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00379834
31861
Not Provided
Anthony D. Realini, West Virginia University
West Virginia University
Not Provided
Principal Investigator: Anthony D Realini, MD West Virginia University
West Virginia University
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP